- Home
- OPAD vs ATOS Comparison
OPAD vs ATOS Comparison
Compare OPAD & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPAD | ATOS |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5M | 24.1M |
| IPO Year | 2020 | 2010 |
Fundamental Metrics
Financial Performance| Metric | OPAD | ATOS |
|---|---|---|
| Price | $3.48 | $2.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $1.83 | ★ $23.00 |
| AVG Volume (30 Days) | 43.6K | ★ 44.2K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $567,812,000.00 | $1,758.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $32.08 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.54 | $0.53 |
| 52 Week High | $6.09 | $7.56 |
Technical Indicators
Market Signals| Indicator | OPAD | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 34.00 | 40.44 |
| Support Level | $0.63 | $2.05 |
| Resistance Level | $5.51 | $2.60 |
| Average True Range (ATR) | 0.24 | 0.14 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 1.82 | 10.26 |
Price Performance
Historical ComparisonAbout OPAD Offerpad Solutions Inc.
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services, including mortgage, listing, renovation, and buyer representation services.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.